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Duchenne muscular dystrophy (DMD) is characterized by in-
creased muscle damage and an abnormal blood flow after mus-
cle contraction leading to a state of functional ischemia. Abun-
dant  evidence  suggests  that  endothelial  circulating  progenitor 
cells (EPCs) play an important role in mediating vascular and 
muscle  repair  mechanisms  and  that  the  stromal  cell-derived 
factor (SDF)-1 α chemokine is responsible for both progenitor 
cell mobilization from the bone marrow to peripheral blood and 
homing to the sites of vascular and tissue injury. Since normal 
neovascularization is disrupted in DMD pathogenesis and may 
contribute ultimately to heart failure and sudden death, the aim 
of the present study is to investigate whether the (SDF)-1 α, and 
EPCs surface receptors in terms of CD34, CD133 and kinase do-
main receptor (KDR) are involved in DMD pathophysiology. In 
the present study, peripheral blood concentrations of circulating 
CD34, CD133, and CD34/ CD 133 progenitor cells were meas-
ured by flow cytometry, together with serum levels of (SDF)-1α 
and hypoxia inducible factor (HIF-1α.), in 28 DMD patients vs. 
20  healthy  age  and  socioeconomic  matching  controls.  Results 
showed a significant increase in the number of mononuclear cells 
bearing  EPC  markers,  HIF-1α  mRNA  expression  and  serum 
(SDF)-1 α, indicating that regeneration is an ongoing process in 
these patients. However, this regeneration cannot counterbalance 
the damage induced by dystrophine mutation.
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Introduction
Duchenne  muscular  dystrophy  (DMD)  represents 
an  X-linked  recessive  disorder  related  to  mutations  in 
the  dystrophin  gene  which  is  located  on  chromosome 
Xp21.1 (1). It is the most common and severe form of dys-
trophinopathies, characterized by progressive and disa-
bling muscle weakness affecting approximately 1 in 3000 
to 4000 male births (2). The disease is characterized by 
ongoing degeneration and regeneration of skeletal muscle 
that leads to replacement of muscle by connective tissue 
and fat (3). In addition to the profound skeletal muscle le-
sions, a distinctive cardiomyopathy has been recognized 
in DMD patients (4, 5). Cardiac lesions, characterized 
by subepicardial fibrosis, particularly of the posterobasal 
portion of the left ventricle (LV), occur in later stages of 
the disease and are apparently progressive (6-8), while 
severe cardiomyopathy develops in the later stages of the 
disease in a large percentage of patients (8). 
Cardiomyopathy is a cardiocytic disease that could 
be followed by a vascular disease. Previous studies sug-
gested that endothelium-mediated relaxation was attenu-
ated in both coronary and peripheral vessels in cardiomy-
opathy patients (9, 10), which means that such patients 
suffer from endothelial dysfunction. Recent studies have 
identified a population of presumably bone marrow–de-
rived cells, called circulating endothelial progenitor cells 
(EPCs) that can be isolated from bone marrow or circulat-
ing mononuclear cells (11). These EPCs express a variety 
of endothelial surface markers including CD34, Cd133 
and KDR (12). They can incorporate into sites of neovas-
cularization (13) and home to sites of endothelial denu-
dation (14). Initial clinical studies demonstrated that risk 
factors  for  atherosclerosis are  associated  with  reduced 
levels of circulating EPCs (15) and that the functional in-
tegrity of the endothelium correlates with the activities of 
EPCs (16). The number of circulating progenitor cells is 
thought to be a marker of vascular function and repair 
capacity and is known to decreases with age (17, 18).
Stromal cell-derived factor (SDF)-1α plays an im-
portant role in neovascularization. (SDF)-1α is an EPC 
chemokine known to be responsible for both progenitor 
cell  mobilization  from  the  bone  marrow  to  peripheral 
blood and homing to the sites of vascular and tissue in-
jury (19, 20). Recently, SDF-1α and its receptor were 
identified as essential in bone marrow retention of he-
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matopoietic stem cells, cardiogenesis, angiogenesis, and 
recruitment of EPCs into ischemic tissue (21, 22). The 
production of SDF-1and other angiogenic factors is me-
diated by HIF-1α, a transcriptional activator that func-
tions as a master regulator of responses to tissue hypoxia/
ischemia (23). HIF-1 is a heterodimer composed of a con-
stitutively expressed HIF-1b subunit and an O2-regulated 
HIF-1α subunit (24). 
Since it was suggested lately that normal neovascu-
larization is disrupted in DMD pathogenesis (25), and 
it is well known that endothelial progenitor cells (EPC) 
play  an  important  role  in  mediating  vascular  repair 
mechanisms, we assessed the number of EPCs with sur-
face markers KDR, CD133, and CD34 progenitor cells 
in DMD patients vs. healthy control subjects. Plasma 
levels of SDF-1 and HIF-1α were additionally investi-
gated. 
Subjects and methods
Subjects were 24 boys diagnosed clinically and at the 
molecular level as having DMD (mean of age (8.1 ± 1.9), 
versus 20 age and socioeconomic matching healthy boys 
(mean of age 8.2 ± 2.2). Patients and controls were chosen 
to be free from any infection and receiving no therapeutic 
treatment known to increase the oxidative stress. Blood 
samples were drawn after their parents’ consent.
Methods
Peripheral blood mononuclear cell isolation and flow 
cytometry
Mononuclear cells were isolated using a Ficoll densi-
ty gradient (Biocoll, Biochrom, Berlin, Germany) accord-
ing to standard protocols as previously described (26). 
For FACS analysis, mononuclear cells were resuspended 
in 100 µl of PBS. Immunofluorescence cell staining was 
performed in duplicate with the use of the fluorescent 
conjugated antibodies CD34– FITC (Becton Dickinson, 
San Jose, USA; clone 8G12) and CD133-APC (Becton 
Dickinson,  San  Jose,  USA;  clone  AC133).  Cell  fluo-
rescence was measured immediately after staining, and 
data were analyzed with the help of CellQuest software 
(FACSCalibur,  Becton  Dickinson,  Heidelberg,  Germa-
ny). Units of all measured components are absolute cell 
counts obtained after the measurement of 250,000 events 
in a lymphocyte gate.
Reverse Transcriptase-polymerase Chain Reaction  
(RT-PCR) Analysis for HIF-1α
Total RNA was extracted from lymphocytes using 
QIAGEN RNA extraction kit (QIAGEN Inc, USA). The 
RNA samples were reverse transcribed using superscript 
reverse transcriptase, using QIAGEN OneStep RT-PCR 
kit  (QIAGEN  Inc  USA,  Clini  Lab).  Primer  sequences 
were: HIF-1α, forward: 5’- CTGTGATGAGGCTTAC-
CATCAGC-3’;  reverse:  5’-CTCGGCTAGTTAGGGTA-
CACTTC-3’; b-actin forward: 5’-GTG GGG CGC CCC 
AGG CAC CA-3’; and reverse: 5’-CTC CTT AAT GTC 
ACG CAC GAT TTC-3’. 5 µl of RT reaction of each 
cDNA were processed for PCR. Ten µL from each PCR 
reaction product were separated on a 2% agarose gel then 
stained with ethidium bromide. The appearance of spe-
cific bands at 283 and 540 bp for HIF-1α and b-actin 
respectively were evaluated under ultraviolet light and 
photographed. Photoes were scanned and quantification 
of each band was carried out using gene tools version 4. 
Each quantified data point was related to its individual 
b-actin (27).
Enzyme-linked immunosorbent assay (ELISA)
Plasma levels of SDF-1 were measured using a com-
mercially available ELISA kit according to the manufac-
turer’s guidelines (R&D Systems, Minneapolis, USA). 
EDTA  plasma  probes  were  centrifuged  for  15  min  at 
10,000 g within 30 min of collection. Probes were aliq-
uoted and stored at −20°C before analysis. The lower de-
tection limit of this assay is 18 pg/ml (28). 
Statistical analysis 
Each experimental condition was performed and ex-
pressed as mean ± SD. Comparisons were made by Stu-
dent’s t-test (two-tailed for independent samples). 
Results
The results are listed in tables and figures. There was 
a significant increase in the number of mononuclear cells 
bearing EPC markers in DMD patients compared to con-
trols. CD 34 (75 ± 6.2 vs. 60 ± 4.8), CD133 (86 ± 4.7 vs. 
75 ± 5.3), KDR (61 ± 4.5 vs. 45 ± 5.6) (table 1 & figure 1). 
Also, cells bearing CD34 CD 133 (44 ± 7.2 vs. 34 ± 4.2), 
CD34 KDR (36.1 ± 6.5 vs. 21.5 ± 8.3) and CD 133 KDR 
(35.4 ± 5.7 vs. 25.5 ± 3.8) were significantly increased 
among DMD patients compared to controls (table 1 & 
figure 1). There was a significant increase in SDF-1 se-
rum level (506.5 ± 75.9 vs. 435 ± 82.6) and HIF-´ α mRNA 
relative expression (3.3 ± 1.2 vs. 1.8 ± 0.6) among DMD 
patients compared to controls.
Discussion
In  the  present  study  the  number  of  mononuclear 
cells bearing EPC markers and HIF-´α together with se-E. Abdel-Salam et al.
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rum SDF-1 were significantly increased indicating that 
regeneration  is  an  ongoing  process  in  DMD  patients. 
CD34  has  been  shown  to  significantly  higher  among 
DMD patients compared to controls. To our knowledge 
circulating CD34 positive cells in blood of DMD patients 
has not been previously measured neither in blood of 
DMD patients nor in animal models. However it can be 
expected that CD34 cells are present in DMD patients 
for tissue regeneration, but their capacity for muscle re-
generation is hindered. The latter assumption can be con-
firmed by the study of Li et al., 2008 (29), who reported 
different proliferative and myogenic abilities of mesen-
chymal stem cells (MSCs) in mdx (mice model for DMD 
compared to the normal C57BL/10 mice). mdx-MSCs 
exhibited  increased  heterochromatin,  larger  vacuoles, 
and  more  lysosomes  under  electron  microscopy  com-
pared to C57BL/10-MSCs. C57BL/10-MSCs formed a 
few myotubes, while mdx-MSCs did not. They indicated 
that at passage 21, mdx-MSCs but not C57BL/10-MSCs 
had gradually lost their proliferative ability. In addition, 
there was a significant difference in the expression of 
CD34. They suggested that the changes in mouse MSC 
behaviour may be influenced by lack of dystrophin pro-
tein in mdx mouse. CD34 is a very interesting stem cell 
marker. It is an EPC/hematopoietic population, which 
is capable of differentiation into cardiomyocytes in vit-
ro (30) and into cardiomyocytes and smooth muscle cells 
in vivo (31). Its pattern and level of expression in muscle 
Table 1. Endothelial progenitor cells surface markers in blood of DMD patients compared to controls.
EPCs DMD patients Controls  t value P value
CD34 75 ± 6.2 60 ± 4.8 9.1 P < 0.0001
CD133 86 ± 4.7 75 ± 5.3 7.2 P < 0.0001
KDR 61 ± 4.5 45 ± 5.6 10 P < 0.0001
CD34 /CD133 44 ± 7.2 34 ± 4.2 6  P < 0.001
CD 34 / KDR 36.1 ±  6.5 21.5 ± 8.3 6.5  P < 0.001
CD 133/ KDR 35.4 ± 5.7 25.5 ± 3.8 8.3 P < 0.0001
Table 2. SDF-1 and HIF-ʹα  mRNA relative expression in DMD patients compared to controls. 
  DMD Controls t
SDF-1 pg/ml 506.5 ± 75.9 435 ± 82.6 3.1 P < 0.01
HIF-ʹ α mRNA
relative expression
3.3 ± 1.2 1.8 ± 0.6 5 P < 0.001
Figure 1. Endothelial progenitor cells surface markers 
in blood of DMD patients compared to controls.
Figure 2. HIF-ʹ α mRNA Relative Expression among DMD 
(3-7) compared to Controls (1-2).
Figure 3. SDF-1 and HIF-ʹ α mRNA relative expression 
among DMD compared to controls.Stromal cell-derived factors in Duchenne muscular dystrophy
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stem cells change as these cells differentiate into myo-
tubes (32). 
In the present study CD133 level was also significantly 
higher among DMD patients compared to controls. This is 
in agreement with Marchesi et al (2008) (33), who found 
that there was an increase in CD133 cells in the blood of 
DMD patients compared with healthy controls and that the 
mean levels of CD133 cells in DMD subjects showed a 
tendency to decrease with advancing age. It was also sug-
gested that the high level of CD133 cells in blood of DMD 
patients may indicate that these cells probably receive more 
specific signals for endothelial differentiation from DMD 
tissues such as a variety of inflammatory cytokines (34). 
CD133-positive cells fraction are mesennchymal stem cells 
(MSCs) with high proliferative potential. When placed in 
appropriate conditions, these cells proved their capacity 
to differentiate into adipocytes, osteocytes, chondrocytes, 
and neuronal/glial cells (35). Also blood-derived CD133-
positive cells were shown to promote the repair of spinal 
cord injury and peripheral nerve defects (36). A subpopula-
tion of human circulating stem cells expressing the CD133 
antigen that can differentiate into endothelial and muscle 
cell types were identified (37). 
KDR is a cell surface receptor and is also a term given 
to vascular endothelial growth factor receptor VEGFR-2. 
In the present study the mononuclear cells bearing KDR 
were significantly increased among DMD patients com-
pared to controls. Data to support this finding are scarce. 
However, it has been recently indicated that there is an in-
creased angiogenesis in the brain of dystrophin-deficient 
mdx mouse, and that this was related to increased levels 
of VEGF and VEGFR (38). In the present study there 
is also a significant increase in CD34 KDR and CD133 
KDR mononuclear cells compared to controls. It ought 
to be mentioned that EPCs are mobilized from the bone 
marrow and contribute to postnatal vasculogenesis and 
vascular homeostasis, and that the number and the in vitro 
function  of  circulating EPCs  are  related  to  endothelial 
function (39). It is believed that EPCs are recruited at high 
frequency by the overexpression of SDF-1 (40), which 
has been shown to be elevated in the present study.
SDF-1 has been shown to be significantly increased 
in blood of DMD patients compared to controls. SDF-1 
is known to play a key role in CD34-positive cell traffick-
ing (41), and to mediate mobilization of haematopiotic 
stem cells and progenitor cells from the bone marrow 
by chemotaxis (42, 43). SDF-1 is known to be induced 
by hypoxia and to exert angiogenic effects (44-46). It 
has been demonstrated that SDF-1 is overexpressed in 
dystrophic muscle, enhances the extravasation of these 
cultured progenitor cells into skeletal muscle after intra-
arterial transplantation (47). This provides proof to the 
finding of the present study.
HIF-1α in the present study was also significantly 
higher among DMD patients compared to controls indi-
cating that a hypoxic condition predominates in DMD. 
Induction of SDF-1 after ischemia is mediated by hypox-
ia-inducible factor-1 (HIF-1) as a transcription factor and 
the central mediator of cellular responses to hypoxic con-
ditions (48). SDF-1 is readily degraded in normoxic cells 
and HIF-2 has been shown to be an important mediator of 
adaptive responses after ischemia (49). HIF-1 regulates the 
expression of hundreds of genes, including those encod-
ing angiogenic cytokines such as stromal-derived factor 
(SDF)-1 (50-52). HIF-1 also mediates cell-autonomous 
responses to hypoxia in endothelial cells (53-55). These 
data suggest an activation of HIF-1alpha in the brain of 
dystrophic mice (38).
We conclude that hypoxic and/or ischemic condi-
tions in muscle tissue of DMD patients initiate regen-
erative processes, which include secretion of (SDF)-1α 
that mobilizes EPC from the bone marrow to peripheral 
blood, homing it to the sites of vascular and tissue inju-
ry. However, the regeneration process does not balance 
the  ongoing  degeneration  caused  by  dystrophin  gene 
mutations in DMD patients. The variability in this bal-
ance may control the severity of phenotypic expression 
in DMD patients.
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